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Περίληψη 
Το ηλεκτρονικό τσιγάρο (ΗΤ), μια συσκευή που μοιάζει πολύ εξωτερικά με τα 
συμβατικά τσιγάρα (ΣΤ), λειτουργεί με μια επαναφορτιζόμενη μπαταρία κι έναν 
ατμοποιητή ο οποίος είναι υπεύθυνος για τη δημιουργία εκνεφώματος νικοτίνης και 
άλλων χημικών, το οποίο εισπνέει ο καπνιστής. Η ολοένα αυξανόμενη χρήση τους 
οδήγησε στην έκφραση σοβαρών προβληματισμών από τον Παγκόσμιο Οργανισμό 
Υγείας και άλλους φορείς όσον αφορά την έλλειψη ερευνών σχετικά με την 
αποτελεσματικότητα και την ασφάλειά τους. Σκοπός της μελέτης αυτής είναι να 
εξετάσει τις βραχυπρόθεσμες επιπτώσεις του ενεργητικού και παθητικού καπνίσματος 
ΣΤ και ΗΤ στον ανθρώπινο οργανισμό όσον αφορά τη λειτουργικότητα και φλεγμονή 
των πνευμόνων. Προσφέρθηκαν να συμμετάσχουν 15 καπνιστές (≥15 τσιγάρα/ημέρα; 7 
γυναίκες) και 15 μη καπνιστές (7 γυναίκες) εθελοντές. Οι καπνιστές υποβλήθηκαν σε 
μια κατάσταση ελέγχου, μία κατάσταση ενεργητικού καπνίσματος ΣΤ και μία 
κατάσταση ενεργητικού καπνίσματος ΗΤ ενώ οι μη καπνιστές υποβλήθηκαν σε μία 
κατάσταση ελέγχου, μία κατάσταση παθητικού καπνίσματος ΣΤ και μία κατάσταση 
παθητικού καπνίσματος ΗΤ. Εξετάστηκαν η πνευμονική λειτουργικότητα, η κοτινίνη 
ορού καθώς και το εκπνεόμενο μονοξείδιο του άνθρακα (CO) και μονοξείδιο του 
αζώτου (FeNO). Αποτελέσματα: Το ενεργητικό και το παθητικό κάπνισμα ΣΤ 
προκάλεσε επιδείνωση της πνευμονικής λειτουργικότητας διάρκειας <1 ώρας. Τόσο το 
ενεργητικό όσο και το παθητικό κάπνισμα ΗΤ δεν επηρέασε σημαντικά την 
πνευμονική λειτουργικότητα. Η κοτινίνη ορού αυξήθηκε σημαντικά σε όλες τις 
καταστάσεις (εκτός από τις καταστάσεις ελέγχου) ενώ το εκπνεόμενο CO αυξήθηκε 
μόνο μετά τη χρήση ΣΤ. Το FeNO δε μεταβλήθηκε σημαντικά σε καμία από τις 
καταστάσεις. Συμπεραίνεται ότι ούτε το ενεργητικό αλλά και ούτε το παθητικό 
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κάπνισμα ηλεκτρονικού τσιγάρου έχει σημαντική επίδραση στη φυσιολογική 
πνευμονική λειτουργικότητα. 
  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 08:53:12 EET - 137.108.70.7
6 
 
Abstract  
The electronic cigarette (e-cigarette), a battery-powered device that simulates 
tobacco cigarettes by vaporizing nicotine and other chemicals into an inhalable vapor, 
is becoming increasingly popular yet the World Health Organization and other 
institutions have expressed serious concerns about the lack of research on its safety and 
efficacy. Our objective was to conduct the first comprehensive and standardized 
assessment of the acute and short term impact of active and passive e-cigarette smoking 
on the function and inflammation of the lungs, as compared to active and passive 
tobacco cigarette smoking. In a randomized crossover trial, 15 smokers (≥15 
cigarettes/day; 7 females) and 15 never-smokers (7 females) volunteered. Smokers 
underwent a control condition, an active tobacco cigarette smoking condition, and an 
active e-cigarette smoking condition. Never-smokers underwent a control condition, a 
passive tobacco cigarette smoking condition and a passive e-cigarette smoking 
condition. Lung function, serum cotinine, exhaled carbon monoxide (CO) and the 
fraction of exhaled nitric oxide (FeNO) were assessed. Results showed that active and 
passive tobacco cigarette smoking resulted in deteriorated lung function lasting <1 
hour. Active and passive e-cigarette smoking did not significantly affect lung function. 
Serum cotinine increased significantly after all conditions (excluding control 
conditions), while exhaled CO increased only following active and passive tobacco 
cigarette smoking. FeNO was not statistically significantly altered in any condition. It is 
concluded that, for the e-cigarettes tested, neither a brief session of active smoking nor 
a 1-hour passive e-cigarette smoking interfere significantly with normal lung function. 
KEYWORDS: e-cigarette, tobacco cigarette, respiratory system, lung 
inflammation, health.  
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Introduction 
History of tobacco and smoking 
History of tobacco and smoking goes back as 18,000 years ago, when mankind 
first encountered tobacco plant species in America. Humans who first populated the 
continent discovered nicotiana tabacum and nicotiana rustica, the two tobacco species 
most consumed today, as they grew natively there. It is much later though that 
cultivation of tobacco took place: estimations range from 5,000-3,000 BC and locate 
the first cultivation site in the Peruvian/Ecuadorean Andes (Gately, 2001; Gilman & 
Xun, 2004).  
The plant had been smoked as a ritual activity well before it was cultivated by 
the Mayans, the Aztecs, the Caribs and lots of other tribes in the western hemisphere 
(Gilman & Xun, 2004). The earliest tobacco use seems to have started by the Mayan 
civilisation, which flourished about 2000 BC - 900 BC, when people began to chew and 
smoke the leaves of the tobacco plant for pleasure and ritual, as well as using the leaves 
for healing the wounds due to its mild analgesic and antiseptic properties (Gately, 
2001). The Mayans though, contrary to the natives of North America who used pipes as 
the most common way of smoking, smoked primitive cigars and cigarettes (Gilman & 
Xun, 2004). 
By the time Christopher Columbus reached America in 1492, tobacco plants 
were abundant all over the continent and there was widespread use of tobacco smoking. 
During an exploratory mission to America’s inland two members of his crew, Rodrigo 
de Jerez and the interpreter Louis de Torres, encountered inhabitants of Cuba smoking 
tobacco leaves and tried it out, becoming the first European smokers in history. It is 
reported that both of them became habitual smokers during the three months’ 
Columbus voyage to the “Indes” (Gately, 2001).  
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In Columbus’ second voyage to America, this time as a conqueror with 17 ships 
and 1200 men, Europeans had become familiar with smoking and watching the Indian 
slaves smoke made them denounce the habit (Gately, 2001). Gonzalo Fernandez de 
Oviedo, military governor of Hispaniola discards smoking as something evil, especially 
harmful which makes the natives “lazy and useless” (Gately, 2001; Gilman & Xun, 
2004). Bartolome de Las Casas, a priest that edited the lost manuscript of Columbus’ 
travels, makes a commentary on smoking identifying that it intoxicates, “makes the 
flesh dull” and decreases appetite. When he tried to convince smokers that tobacco was 
evil, they told him it was beyond their control to stop it. Addiction was noticed but not 
understood, it was simply perceived as sin (Gately, 2001). 
In Europe the public learned how to smoke and the consequences of smoking 
were not yet known; the encounter with tobacco and the smoking habit was something 
new, a new costly experience affordable only by the upper class. However, from a 
luxury it became available to the majority of the people rather quickly (Gilman & Xun, 
2004). This was assisted by the fact that tobacco was recognized as a means of 
promoting health. In 1571 Nicolas Monardes, a famous physician of Seville, presented 
tobacco as “the holy herb” that could cure illness both physical and psychic, help 
someone relax and even cure syphilis, a disease imported from the New World.  Soon, 
smoking incorporated in culture and art (Gilman & Xun, 2004). In England tobacco 
was considered especially effective against bubonic plague, which resulted in greater 
spread of the habit even in children (Gately, 2001). 
Outside Europe, across the Ottoman Empire smoking proliferated with great 
speed. In Central Asia and India the most favourite way of smoking was mixing 
tobacco with other herbs and sandal-wood through a water-pipe, the hookah. 
Portuguese and French traders introduced pipe smoking to the African continent. Then, 
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smoking expanded to Japan in April 1600 by an Englishman and just a decade later 
even children had acquired the habit. Via Japan and South China Sea smoking was 
brought by traders to China and it instantly became a beloved habit for the Chinese, 
who related it to all tea rituals and made it a daily necessity. Smoking rapidly evolved 
into a global practice, an endemic (Gilman & Xun, 2004).  
 This new habit, adopted by all classes of society in everyday life, now aroused a 
number of problems. At a time it was considered that smoking caused workers to 
neglect their duties. There was also the fear of fire outbreaks from a careless smoker, 
since most of the houses and furniture was wooden. Most significant though were the 
medical concerns on the harmful consequences that aroused in the early 17
th
 century 
both in Europe and in the East (Gilman & Xun, 2004).  
In few European countries like Switzerland and the German state of Saxony 
tobacco was not welcome and smoking was prohibited. Smokers were even sentenced 
to death in Luneburg, a penalty that was valid till 1691 (Gately, 2001). Similar efforts 
were made in countries outside Europe by both rulers and clergy. The Ottoman sultan 
Murad IV (1623-1640) was probably the first governor to prohibit smoking. Anti-
smoking laws and bans were also reinforced in China from the Chongzhen emperor and 
the following dynasty, in England by James I and in Russia by the Patriarch of 
Moscow, who forbade the sale of tobacco and punished smokers by whipping their 
nostrils so badly that no skin remained. Still, none of those prohibitions managed to 
refrain people from smoking (Gilman & Xun, 2004). 
 It did not take long for rulers to realise that they were unable of suppressing the 
smoking habit; therefore they attempted to control it through state monopoly. This 
policy brought them wealth, established their domination and satisfied the populace 
(Gilman & Xun, 2004).  
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The English language term “smoking” appears in the late 18th century, 
replacing descriptions such as “drinking smoke” (Lloyd & Mitchinson, 2007). Tobacco 
eventually was smoked not only in cigars for the privileged and in pipes for the masses 
but also in cigarettes (Gilman & Xun, 2004). In the United States tobacco use reached a 
plateau until the American Civil War in 1860s, when the industrialisation of cigarette 
production took place from the craftsman James Bonsack (Burns, 2006).  
Anti-smoking groups in Nazi Germany began to take action and published 
articles against the consumption of tobacco in the journal Der Tabakgegner (The 
Tobacco Opponent) in 1912 and 1932. Unfortunately, these groups quickly lost popular 
support. By the end of the Second World War, American cigarette manufacturers 
quickly re-entered the German black market. Illegal smuggling of tobacco took place 
and the anti-smoking campaign met an inglorious end.  In 1948-9 a total of 93,000 tons 
of tobacco was sent to Germany by the United States as part of the Marshall Plan 
(Proktor, 2000).  
More and more scientific evidence was brought to light in the 1980s, obliging 
tobacco companies to claim contributory negligence as the consequences of smoking on 
human health were unknown or missing evidence. No significant action was taken by 
health authorities until 1998, when the four largest United States tobacco companies 
and the Attorneys General of 46 states signed the Tobacco Master Settlement 
Agreement ("Tobacco Master Settlement Agreement," 1998). This agreement forbade 
tobacco advertisement targeting in young people below 18 years of age and imposed 
penalties for health compensation; eventually more tobacco companies took part and it 
ended the largest civil settlement in United States history, even though finally it was not 
applied in several magazines, thus failing to protect young people from these 
advertisements (King & Siegel, 2001). 
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Since then, a lot of anti-smoking laws, policies and campaigns tried to safeguard 
human’s right to breathe fresh air, encouraging smokers to quit, prohibiting smoking to 
common places and aiming at smoke-free homes. In Europe and the United States rates 
of smoking display a significant decline, in the developing world however tobacco 
consumption continues to rise (WHO, 2011).  
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From “holy herb” to today’s scourge 
 Tobacco plant was initially used for medical and ritual purposes but eventually 
it ended up smoked for recreational purposes. The habit of smoking has spread 
worldwide and has become a favourite activity for lots of people, in different kind of 
places and times of the day. At present, tobacco consumption is increasing globally, 
though it is decreasing in some high-income and upper middle-income countries 
(WHO, May 2012.). According to a report published on 2008 from the World Health 
Organisation, Greece was 6th in consuming tobacco worldwide, having 48% age-
standardised adult smoking prevalence (WHO, 2008b).  
WHO identifies smoking as a “leading cause of death, illness and 
impoverishment” (WHO, May 2012.). Despite the global initiatives and the 
implementation of measures against the tobacco epidemic, the tobacco scourge kills 
one person every six seconds. Approximately half of the smokers will eventually die of 
a tobacco-related disease. In total, smoking kills nearly 6 million people each year, of 
whom more than 5 million are users and ex users and more than 600.000 are non 
smokers exposed to second-hand smoke (WHO, May 2012.).  
 Breathing other people's cigarette smoke is known as passive, involuntary or 
second-hand smoking (SHS). It can also be called ‘environmental tobacco smoke’ 
("ASH Research Report: SecondHand Smoke ", April 2011). SHS is a mixture of the 
‘mainstream’ smoke which is exhaled by the smoker and ‘sidestream’ smoke produced 
by the burning cigarette, which accounts for most of SHS (World Health Organisation, 
2006).  
Passive smoking kills approximately 600,000 people per year; furthermore there 
is substantial evidence that no safe level of exposure to SHS exists. Tobacco smoke 
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contains more than 4000 chemicals; 250 of them are proved to be deleterious for human 
health and at least 50 of them are identified as carcinogenic (WHO, May 2012.). 
Both active and passive smoking have acute and long-term effects on health by 
causing damage in nearly all systems of the human organism and thereby resulting in 
high morbidity and increased risk for premature death (table 1) (World Health 
Organisation, 2004, 2006).  
Table1. Diseases and other adverse health effects for which smoking is identified as a 
cause [12-13]   
Active smoking consequences  
Cancer Bladder cancer, Cervical cancer, Esophageal cancer, Kidney 
cancer, Laryngeal cancer, Leukemia, Lung cancer, Oral cancer, 
Pancreatic cancer, Stomach cancer  
Cardiovascular 
diseases  
Abdominal aortic aneurysm, Atherosclerosis, Cerebrovascular 
disease, Coronary heart disease 
 
Respiratory 
diseases  
 
Chronic obstructive pulmonary disease, Pneumonia, Respiratory 
effects in utero, Respiratory effects in childhood and 
adolescence, Respiratory effects in adulthood, Other respiratory 
effects  
Reproductive 
effects  
Fetal death and stillbirths, Fertility, Low birth weight, Pregnancy 
complications 
 
Other effects  Cataract, Diminished health status/morbidity, Hip fractures, Low 
bone density, Peptic ulcer disease  
 
Passive smoking consequences 
Cardiovascular 
disease 
Coronary heart disease, Stroke, Atherosclerosis 
Respiratory 
diseases (adult) 
Acute respiratory symptoms, Chronic respiratory symptoms, 
COPD, Asthma onset and worsening, Pulmonary function 
decline, Bronchitis and pneumonia, Acute respiratory infections 
  
Respiratory 
diseases 
(children) 
Lower respiratory tract infections, Middle ear effusions, Chronic 
cough, asthma, lung growth and pulmonary function affection 
Cancer Lung cancer, Breast Cancer, Nasal Sinus Cavity Carcinoma 
 
Reproductive and 
Developmental 
Effects 
Sudden Infant Death Syndrome, Preterm Delivery, Low Birth 
Weight, Childhood Cancer(Leukemias, Lymphomas, Brain 
tumors) 
Other Odor annoyance, Eye irritation, Nasal irritation 
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Literature Review: Smoking and lung function 
 
Active smoking and lung function 
Active smoking triggers a number of biologic processes like oxidant stress, 
inflammation and a protease/antiprotease imbalance that cause irritation and injury both 
in airways and alveoli. If this injury persists it ultimately results to the development of 
chronic obstructive pulmonary disease (COPD) (U.S. Department of Health and Human 
Services, 2010). 
COPD refers to a group of diseases that cause airflow blockage and breathing-
related problems and includes emphysema, chronic bronchitis, and in some cases 
asthma (Rennard, 1998). COPD is a leading cause of morbidity and mortality 
worldwide and results in an economic and social burden that is both substantial and 
increasing (Lopez, et al., 2006). Across the world, cigarette smoking is the most 
commonly encountered risk factor for COPD (GOLD, 2011).  
Chronic tobacco use also accounts for a number of respiratory health problems: 
all major respiratory symptoms like cough, phlegm, and dyspnea, acute respiratory 
illnesses, increased non-specific bronchial hyperesponsiveness and asthma-related 
symptoms (i.e. wheezing) (U.S. Department of Health and Human Services, 2010; 
Urrutia, et al., 2005; World Health Organisation, 2004). Furthermore, there is sufficient 
evidence that active smoking causes a significant deterioration in lung function which 
starts earlier in age and is accelerating with the passing of years (Urrutia, et al., 2005; 
World Health Organisation, 2004; Yang & Yang, 2002), as well as a slowed growth of 
lung function in adolescents (D. R. Gold, et al., 1996; World Health Organisation, 
2004). These risks increased with increasing number of cigarettes smoked per day 
(Urrutia, et al., 2005; World Health Organisation, 2004).  
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In accordance to these findings, smokers with normal lung function have 
significantly lower values for forced expiratory volume in 1 second (FEV1) to forced 
vital capacity (FVC) ratio (FEV1/FVC) and forced expiratory flow between 25% and 
75% of FVC (FEF25-75) than did non smokers, suggesting the presence of subclinical 
airflow limitation possibly due to increased resistance to airflow, even though this 
impairment was not of sufficient magnitude to be regarded as clinical evidence of 
airway obstruction (Yang & Yang, 2002). A deterioration of FEV1 and FEV1/FVC were 
also directly associated with the number of cigarettes smoked per day (Urrutia, et al., 
2005). 
Furthermore, smoking reduces the production of endogenous nitric oxide 
(NO)(Kharitonov, Robbins, Yates, Keatings, & Barnes, 1995) by cells lining the 
respiratory tract possibly via down-regulation of both endothelial NO synthase (eNOS) 
and inducible NO synthase (iNOS) (Hoyt, et al., 2003). Synthesis and functions of 
nitric oxide are depicted in figure 1. Since endogenous NO is important in defending 
the respiratory tract against infection, in counteracting bronchoconstriction and 
vasoconstriction and in inhibiting platelet aggregation, this effect may contribute to the 
increased risks of chronic respiratory and cardiovascular disease in cigarette smokers. 
Significantly lower concentrations of the exhaled nitric oxide fraction (FeNO) are 
found in smokers in a dose-dependent way, reducing as cigarette consumption 
augments (Kharitonov, et al., 1995; Sundy, et al., 2007). 
Chronic lung disease is normally a long-term process. However, even brief 
exposures to air pollution stimulate mechanisms that contribute to its development 
(Flouris, 2009; Flouris, et al., 2009). Indeed, production growth factors and type 1 
procollagen in the small airways is rapidly increased within the first few minutes of 
smoke inhalation (Churg, Tai, Coulthard, Wang, & Wright, 2006). Within five minutes  
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Figure 1. Synthesis and functions of nitric oxide (adopted from Abba et al., 2009)  
 
leucocytes start bonding to endothelial cells (Lehr, et al., 1991), while lung 
inflammation is increased within the first 15 minutes (Yates, Breen, & Thomas, 2001). 
By 20 minutes, platelet activation is increased (Davis, Shelton, Watanabe, & 
Arnold, 1989), while within one hour nearly all systems are affected (Flouris, et al., 
2009; Flouris, Metsios, Jamurtas, & Koutedakis, 2008; Flouris, Vardavas, Metsios, 
Tsatsakis, & Koutedakis, 2010; Metsios, et al., 2007).  
Limited data from human studies on the acute effects of smoking on lung 
function show that smoke exposure leads to tissue damage by several mechanisms. 
Smoking acts chemotactic to neutrophils and macrophages, attracting and activating 
these cells shortly after the first puffs of a cigarette. Increased chemotactic activity of 
the monocytes present at the bronchoalveolar lavage fluid (BALF) was also observed. 
In addition, active smoking increases the air space epithelial permeability within one 
hour of cigarette smoking causing serious impairment of the epithelial barrier which in 
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turn could lead to destruction of the lung parenchyma (van der Vaart, et al., 2005; van 
der Vaart, Postma, Timens, & ten Hacken, 2004).  
Another mechanism is the inhibition of fibroblasts, which are important in 
repair processes in the lung. Repetition of acute smoke exposure could thus result to 
irreversible damage. Furthermore, smoking suppresses the number of eosinophils either 
due to the anti-inflammatory properties of CO or due to a possible change in the Th1-
Th2 type cytokine balance (van der Vaart, et al., 2005; van der Vaart, et al., 2004).  
FeNO is also significantly reduced acutely, even by smoking a single cigarette, 
although this seems to be a transient effect (Kharitonov, et al., 1995). The greater short-
term (hours to days) exposure to inhaled tobacco smoke was associated with greater 
decreases in FeNO levels (Sundy, et al., 2007). 
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Passive smoking and lung function 
 
 SHS consists of ‘sidestream’ and ‘mainstream’ smoke, which both contain 
thousands of fine particles and chemicals. The number of smokers, the rhythm of their 
smoking and the total volume of air in which smoke is diffused are the main factors 
influencing the exact composition of SHS, which is fairly different whenever one or 
more of these factors change ("ASH Research Report: SecondHand Smoke ", April 
2011; World Health Organisation, 2006). 
The most studied carcinogenic compounds of SHS include polycyclic aromatic 
hydrocarbons, nitrosamine compounds, heterocyclic aromatic amines, and other 
miscellaneous organic compounds. Tobacco specific N-nitrosamines (TSNA) are 
powerful carcinogens that affect various tissues such as the oesophagus, the nasal 
cavity, and the lung (A. D. Flouris, C. I. Vardavas, et al., 2010).  
Chronic repeated exposure to SHS causes acknowledged long-term health 
effects summarised above (Τable 1). However, passive smoking has also significant 
immediate health effects: it can exacerbate respiratory problems, trigger asthma attacks, 
reduce coronary blood flow, irritate eyes and cause headaches, coughs, sort throats, 
dizziness and nausea ("ASH Research Report: SecondHand Smoke ", April 2011). 
Acute effects of SHS on the respiratory system are illustrated in Figure 2. As far as lung 
function is concerned, SHS increases lung inflammation and declines lung function 
(Eisner, et al., 2007; Flouris, et al., 2009; World Health Organisation, 2006); even after 
as little as 1 hour’s moderate exposure (Flouris, et al., 2009).   
 In specific, Flouris et al. (Flouris, et al., 2009) showed that one-hour exposure to 
SHS at bar/restaurant levels generates significant decrements on lung function, FEV1, 
FEV1/FVC, maximum expiratory flow at 75% of expired vital capacity (MEF75%), 
MEF50%, and MEF25%. These results closely resembled the airway obstruction apparent 
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Figure 2. Acute effects of passive smoking to the respiratory system (adopted with 
permission from Flouris et al.,2010)  
 
in smokers. The mechanisms proposed are airway irritation, oxidative stress, 
inflammation and direct induction of growth factors resulting in airway remodelling 
(Flouris & Koutedakis, 2011; A. D. Flouris, C. I. Vardavas, et al., 2010). Clinical 
implications of brief SHS exposure on the respiratory system like nasal congestion, 
irritation and increased rhinitis seem to develop due to nasal mucociliary clearance, C-
fiber activation and epithelial permeability to environmental allergens (Flouris & 
Koutedakis, 2011; A. D. Flouris, C. I. Vardavas, et al., 2010).   
 Furthermore, within the first 15 min of moderate SHS exposure there is a 
decline in FeNO levels, which may be caused by the decreased production of NOS 
through the mechanism of negative feedback due to high levels of nitrogen oxides 
present in tobacco smoke. Other possible mechanisms include an increased breakdown 
or modification of nitric oxide by SHS oxidants or a SHS-induced accelerated uptake of 
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nitric oxide (A. D. Flouris, C. I. Vardavas, et al., 2010). These deleterious effects of 
SHS are exacerbated when physical activity follows the SHS exposure, particularly in 
less fit individuals (Flouris & Koutedakis, 2011; Flouris, et al., 2012; A. D. Flouris, G. 
S. Metsios, A. Z. Jamurtas, & Y. Koutedakis, 2010). 
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The introduction of the electronic cigarette  
 
As the number of smokers worldwide is reaching record highs and anti-smoking 
policies are propagating (Flouris & Oikonomou, 2010; A. D. Flouris, C. I. Vardavas, et 
al., 2010), the industry of alternative smoking products is in the froth of excitement 
about the potential of increasing market shares and revenues. One of the most recently-
introduced products in the germane market is the electronic cigarette (e-cigarette), also 
known as electronic nicotine delivery systems (ENDS), a battery-powered device that 
simulates tobacco cigarettes by vaporizing nicotine and other chemicals into an 
inhalable vapour. They consist of a rechargeable battery, a vaporization chamber and 
the liquid nicotine cartridge (figure 3).  
Manufacturers claim that the liquid cartridge mainly contains nicotine and 
propylene glycol, a low toxicity compound found in many products of everyday life. 
Although believed to be safe, propylene glycol exposure is related to irritation of the 
respiratory system and asthma (Choi, Schmidbauer, Spengler, & Bornehag, 2010; 
Wieslander, Norback, & Lindgren, 2001). 
 
Figure 3. The electronic cigarette device (adopted by Center for Public Health and 
Tobacco Policy - http://www.tobaccopolicycenter.org) 
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Three analyses of the liquid content are available so far. FDA analysis showed 
that nicotine release was not uniformly released in each puff and detected nicotine in 
cartridges labelled as containing zero nicotine. Moreover, TSNA and tobacco specific 
impurities were found at low levels as well as diethylene glycol – a highly toxic 
compound (Westenberger, 2009). Another analysis of an e-cigarette from a private 
enterprise tracked polycyclic aromatic hydrocarbons in the liquid in addition to the 
carcinogenic nitrosamines detected (Laugesen, 2008). The third report comes from the 
Greek institute “Demokritos” and besides the presence of propylene glycol does not 
detect any of the above compounds (Leondiadis, 2009).  
The scarce available data suggests that sales of e-cigarettes are increasing 
(Pauly, Li, & Barry, 2007), while Google searches for “electronic cigarettes” have 
increased by 5000% over the past 2 years (Yamin, Bitton, & Bates, 2010). This 
technology became popular despite serious concerns expressed by the World Health 
Organization, the US Food and Drug Administration (FDA), and a number of Health 
Ministries worldwide (FDA, 2009; World Health Organisation, 2010) about the lack of 
research on its safety and efficacy (Etter, Bullen, Flouris, Laugesen, & Eissenberg, 
2011; Flouris & Oikonomou, 2010).  
Electronic cigarettes were initially proposed as a cessation aid by manufacturers 
but as there were no data available WHO asked companies not to promote them as 
therapeutic aids (WHO, 2008a; WHO study group on tobacco product regulation, 
2009). Recently, Caponnetto et al. showed that three Caucasian smokers with a 
documented history of recurring relapses were able to quit and to remain abstinent for 
at least six months after taking up a cigarette. Authors claim that besides delivering 
nicotine to the lung, e-cigarette use preserves some of the gestures linked with the 
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smoking habitude (for example the hand-to-mouth action of smoking), helping in this 
way on smoking cessation (Caponnetto, Polosa, Russo, Leotta, & Campagna, 2011). 
However, according to a technical report published by WHO (WHO study 
group on tobacco product regulation, 2009), ENDS pose significant public health issues 
and raise questions for tobacco control policy and regulation. Manufacturers have not 
fully disclosed the chemicals used in ENDS; there are few data on their emissions or 
actual human exposure; their health effects have not been studied; and their marketing 
and use could undermine public smoking bans, which are important tobacco control 
interventions. The products could also undermine smoking cessation efforts by 
proposing unproven devices for smoking cessation in the place of products of proven 
efficacy. ENDS might also sabotage the prevention of tobacco use because of their 
appearance and marketing as safe alternatives to tobacco products for nontobacco users, 
including children. 
Indeed, e-cigarette advertisements and related promotion activities are spreading 
to adolescents, mainly through the Internet (WHO study group on tobacco product 
regulation, 2009). A study of 4,341 middle and high school students in Korea showed 
that 10.2% had ever seen or heard of e-cigarettes, while 0.5% of them had used an e-
cigarette. Male gender, perception of peer influence, satisfaction in school life and 
cigarette smoking experience were the factors determined to be statistically significant 
predictors of e-cigarette experience (Cho, Shin, & Moon, 2011). 
Limited data available on ENDS use yield further concerns; it has been shown 
that they contain carcinogenic compounds (although in lower concentrations compared 
to tobacco cigarettes and similar to those existing in nicotine medications) (FDA, 2009; 
Laugesen, 2008); nicotine was present in all cartridges (including samples identified as 
containing no nicotine) (Hadwiger, et al., 2010; Westenberger, 2009); and similarly 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 08:53:12 EET - 137.108.70.7
27 
 
labelled cartridges emitted markedly different amounts of nicotine in each puff 
(Trtchounian, Williams, & Talbot, 2010; Westenberger, 2009).  
Compared with conventional cigarettes, e-cigarettes require stronger vacuums 
(suction) to smoke and the effects of this on human health could be adverse. The 
amount of aerosol produced by e-cigarettes decreases as smoking continues, which 
eventually necessitates increasing puff strength to produce aerosol. Furthermore, the 
decreased efficiency of aerosol production during e-cigarette smoking makes dosing 
non-uniform over time and calls into question their usefulness as nicotine delivery 
devices (Trtchounian, et al., 2010). 
In a recent study where 6 different e-cigarette brands were tested authors 
conclude that design flaws, lack of adequate labelling and concerns about quality 
control and health issues indicate that regulators should consider removing ENDS from 
the market until their safety can be adequately evaluated (Trtchounian & Talbot, 2011).  
In the first clinical laboratory model for evaluating the acute effects of e-
cigarettes in 32 ENDS-naive smokers, no significant changes were observed in plasma 
nicotine, heart rate and exhaled CO after use of 2 brands of e-cigarettes, contrary to the 
pronounced increase noticed 5-15 minutes after traditional cigarette use. Interestingly, 
e-cigarettes suppressed nicotine/tobacco abstinence symptoms for as long as 96 hours 
after use, although not as effectively as traditional cigarettes and had positive ratings of 
product acceptability (Vansickel, Cobb, Weaver, & Eissenberg, 2010).  
In another clinical study, 40 ENDS-naive smokers were randomised to use e-
cigarettes containing 16 mg nicotine or 0 mg capsules, Nicorette nicotine inhalator or 
their usual cigarette. The 16 mg e-cigarette alleviated desire to smoke after overnight 
abstinence was well tolerated and had a pharmacokinetic profile more like the Nicorette 
inhalator than a tobacco cigarette (Bullen, et al., 2010).  
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In contrast to the previous laboratory reports that claim that ENDS does not 
increase plasma nicotine significantly (Vansickel, et al., 2010) or increase plasma 
nicotine in levels lower than nicotine inhalers or tobacco cigarettes (Bullen, et al., 
2010), Etter et al. found substantial amounts of cotinine in the saliva of ENDS users, 
similar to conventional cigarette smokers levels and higher than found in NRT users 
(Etter & Bullen, 2011). According to the authors, this may be explained by important 
variations of puffing topography, experience in ENDS use or may apply only for the e-
cigarettes brands used. 
Regarding pulmonary effects of ENDS use only one study is published so far 
(Vardavas, et al., 2011). Researchers found that using an e-cigarette ad libitum for 5 
minutes, even though it does not seem to affect lung function, it leads to a statistically 
significant decrease in exhaled FeNO. Moreover, an increase in flow resistance by 
approximately 18% as well as an increase in impedance and overall peripheral airway 
resistance was noted. These effects are similar to those seen with tobacco smoking and 
in experimental studies appear prior to changes in FEV1 and PEF; thus authors imply 
that e-cigarette use has a significant health effect on lung function and inflammation 
which may not be of major clinical value yet but needs further studies to be assessed 
(Vardavas, et al., 2011).   
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Aim of this study 
Long-term effects of conventional cigarette smoking on lung function are well 
studied; this does not apply though for the acute effects for which there are scarce data.  
However, acute effects are equally important to be elucidated both in active and passive 
smoking; In active smoking it is clear that there is no safe level or tobacco consumption 
(World Health Organisation, 2004) and as far as passive smoking recent data show that 
even brief exposure to SHS provokes significant decline in lung function (Flouris, 
2009; Flouris & Koutedakis, 2011; Flouris, et al., 2009; A. D. Flouris, C. I. Vardavas, 
et al., 2010). There is no published study examining the acute effects of active smoking 
on lung function and there are only a few studies on passive smoking (Flouris, 2009; 
Flouris & Koutedakis, 2011; Flouris, et al., 2009; A. D. Flouris, C. I. Vardavas, et al., 
2010). 
After the introduction of the electronic cigarette in the market, it was accepted 
with enthusiasm rather than skepticism. However, limited data exist on its efficacy and 
safety of use (Flouris & Oikonomou, 2010), no study has been published so far on its 
consequences from passive smoking and only one study examined its effects on lung 
function (Vardavas, et al., 2011). 
In this study we investigated the acute and short term impact of active smoking 
on lung function and inflammation. Moreover, we assessed for the first time both active 
and passive e-cigarette smoking regarding its acute impact on lung function, as well as 
compared its effects with these of the conventional cigarette.  
We hypothesized that active smoking has immediate effects on lung function, 
based on the knowledge that lung inflammation is stimulated only minutes after smoke 
inhalation (Yates, et al., 2001) and investigated the existence and magnitude of this 
impact. Regarding the electronic cigarette, we attempted to detect possible harmful 
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changes on human pulmonary function both from its use and from the inhalation of its 
vapor and examine if these are of clinical significance.   
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Methodology 
 
Materials and Methods 
Participants 
Two groups of adult volunteers participated: 15 smokers (≥15 cigarettes/day; 7 
females; 36.83±9.85 years; 25.61±4.05 BMI; 22.46±18.43 pack years) and 15 never-
smokers (7 females; 28.87±10.45 years; 23.59±2.99 BMI). All volunteers provided 
written consent (the form of the written consent is attached on the supplement). 
Exclusion criteria included pregnancy, signs of acute illness, abnormal spirometry 
(conducted at baseline during each condition) and/or other evidence of pulmonary 
disease or other chronic conditions, and use of medication known to influence lung 
function. Smokers reporting previous use of e-cigarettes were also excluded for ethical 
reasons (i.e., possible relapse into tobacco cigarette smoking) (Eissenberg, 2010; 
Vansickel, et al., 2010). All women participants were premenopausal with regular 
menstruation and were tested during the late luteal phase of their menstrual cycle.  
 
Experimental Design 
The study was conducted according to the principles expressed in the Declaration of 
Helsinki and was approved by the University of Thessaly Ethics Review Board 
(document attached on supplement). Each group attended three conditions administered 
in a random order and separated by a minimum of five days (figure 4). The group of 
smokers underwent a control condition (ACTIVECON), an active tobacco cigarette 
smoking condition (ACTIVETOB), and an active e-cigarette smoking condition 
(ACTIVEE-CIG), each lasting 30 minutes. In ACTIVECON, smokers were asked to  
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Figure 4. Flowchart of the participant recruitment and assessment process 
 
pseudo-smoke an unlit-cigarette from a brand  of  their  choice.  In ACTIVETOB, 
smokers were asked to smoke two tobacco cigarettes from a brand of their choice. In 
ACTIVEE-CIG, smokers were asked to puff an e-cigarette in order to absorb enough 
nicotine to match two of their favorite tobacco cigarettes. 
 The group of never smokers underwent a control condition (PASSIVECON), a 
passive tobacco cigarette smoking condition (PASSIVETOB), and a passive e-cigarette 
cigarette smoking condition (PASSIVEE-CIG), each lasting one hour. In PASSIVECON, 
participants were exposed to normal room air. In PASSIVETOB and PASSIVEE-CIG, 
participants were exposed to air polluted with tobacco cigarette smoke and e-cigarette 
vapor, respectively, adjusted to simulate bar/restaurant levels (Flouris, et al., 2009). 
Prior to each condition, participant’s exhaled CO was measured. As previously 
reported (Bullen, et al., 2010), the assigned condition was allocated if CO was ≤15 ppm 
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in smokers and ≤1 ppm in never smokers. If CO was >15 ppm in smokers, >1 ppm in 
never-smokers, or the participant reported active smoking or excessive passive smoking 
in the previous 10 hours, the condition was rescheduled. For never-smokers, previous 
measurements were performed before, immediately after, and one hour after active and 
passive smoking (figure 3). We evaluated forced FVC, FEV1, FEV1/FVC, peak 
expiratory flow (PEF), and forced expiratory flow in the middle 50% of FVC (FEF25-
75). The fraction of exhaled nitric oxide (FeNO) was monitored as a marker of airway 
inflammation. Exhaled CO and serum cotinine were assessed as indicators of active and 
passive e-cigarette and tobacco cigarette smoking. 
 
Active Smoking Protocol 
In the ACTIVECON condition, smokers were asked to pseudo-smoke an unlit-
cigarette from a brand of their choice for 30 minutes. In the ACTIVETOB condition, 
smokers were asked to smoke two tobacco cigarettes from a brand of their choice 
within 30 minutes. Finally, in the ACTIVEE-CIG condition, smokers were asked to take a 
number of puffs from an e-cigarette device (Giant, Nobacco G.P., Greece) within 30 
minutes. A new cartridge (within its expiration date) and a fully charged battery were 
used for each session. The e-cigarette liquid used (Nobacco USA Mix, Nobacco G.P., 
Greece) had a “tobacco taste” and contained 11mg/ml of nicotine, which is an average 
concentration since the range of nicotine content in e-cigarette liquids usually ranges 
between 0 to 36 mg/ml. Previous research has shown that a given number of puffs on 
an e-cigarette result in significantly less nicotine absorption compared to that generated 
by the same number of puffs from a tobacco cigarette (Eissenberg, 2010; Vansickel, et 
al., 2010). Thus, results from studies maintained an equal number of puffs across 
products may reflect a lower nicotine dose instead of reduced particulates, tars and CO.  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 08:53:12 EET - 137.108.70.7
34 
 
Therefore, it was deemed appropriate to calculate the number of puffs for each 
participant in the ACTIVEE-CIG condition based on (i) the nicotine content of their 
tobacco cigarette, (ii) the tobacco cigarette to e-cigarette nicotine absorption ratio, (iii) 
the nicotine concentration in the e-cigarette liquid, as well as (iv) the number of puffs 
required to consume 1 ml of liquid in an e-cigarette. The information required in order 
to derive (ii), (iii), and (iv) was obtained through a pilot study using an independent 
sample of 178 e-cigarette smokers that were previous tobacco cigarette smokers.  
Given that the vast majority e-cigarettes are sold online (Etter, et al., 2011), the 
internet is the most appropriate means to reach users. We therefore posted two survey 
forms, in English and Greek, on the survey website www.surveymonkey.com over a 3-
month period between September 14 2011 and December 13 2011. Links to the survey 
were posted on international (e-cigarette-forum.com, minicigarette.net, 
vaporboards.com, electroniccigaretteforum.net, new-smoke.com, vaportalk.com, 
vaporgossip.com) and Greek (e-kapnisma.gr) websites that provide information about 
e-cigarettes and/or sell them. Eligible participants were people who declared that they 
were previous tobacco cigarette users and were currently using e-cigarettes and who 
could also provide the brand names of both the tobacco cigarette and the e-cigarette that 
they had used most often. Participants were asked to respond to five survey questions: 
“1. On average, how many tobacco cigarettes did you use to smoke per day?” (response 
from 1 to >120 with increments of 1); “2. What brand of tobacco cigarettes did you use 
to smoke?”; “3. What is the quantity (in mg) of nicotine in the liquid you use for your 
e-cigarettes?” (Response from 1 to >36 with increments of 1); “4. On average, how 
many ml of e-cigarette liquid do you use per day?” (Response from 0.5 to >10 with 
increments of 0.5); “5. On average, how many times do you puff your e-cigarette in 
order to smoke 1ml of liquid?” (Response from 1 to >200 with increments of 1). 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 08:53:12 EET - 137.108.70.7
35 
 
A total of 178 e-cigarette users completed the survey. Of those, 141 completed 
the English survey, while 37 completed the Greek survey. Responses from both surveys 
were analyzed simultaneously. Results from questions 1 through 4 revealed that 
nicotine consumption via e-cigarettes was 1.5 times higher than nicotine consumption 
via tobacco cigarettes. Assuming that the users aimed for the same effect, this means 
that the average tobacco cigarette/e-cigarette nicotine absorption ratio is 1.5. Results 
from the 5
th
 question demonstrated that the median number of puffs required to 
consume 1 ml of e-cigarette liquid was 50. Thus, e-cigarette puffs can be corrected to 
match a tobacco cigarette in terms of nicotine absorption after taking into account the 
nicotine content of the e-cigarette liquid. Based on the above, the e-cigarette puffs 
equivalent to that of 1 tobacco cigarette, while controlling for nicotine absorption, was 
calculated as: 
e-cigarette puffs = (TOBNIC · 1.5 · 50) / eCIGNIC 
where TOBNIC is the tobacco cigarette nicotine content (in mg), 1.5 is the average 
tobacco cigarette/e-cigarette nicotine absorption ratio, 50 is the average number of 
puffs required to consume 1 ml of liquid, and eCIGNIC is the e-cigarette liquid nicotine 
content (in mg) per ml. Since the above equation was used to calculate the total number 
of puffs during the ACTIVEE-CIG condition, the result was multiplied by 2 since that 
was the number of tobacco cigarettes smoked in the ACTIVETOB condition. Based on 
the obtained information, the e-cigarette puffs in the ACTIVEE-CIG condition were 
calculated as: [[tobacco cigarette nicotine content (in mg) · 1.5 · 50] / e-cigarette liquid 
nicotine content (in mg) per ml] · 2. The total number of puffs during the ACTIVEE-CIG 
condition ranged from 3 [for a subject who smoked “extra light” cigarettes (0.2 mg of 
nicotine per cigarette)] to 14 (for two subjects who smoked cigarettes containing 1 mg 
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of nicotine per cigarette). The median puff number was 11, and the mean±sd puff 
number was 10.4±2.7. 
 
Passive Smoking Protocol 
In the PASSIVECON condition, never-smokers were exposed to normal room air 
for one hour inside a 60m
3
 environmentally controlled chamber (air temperature: 21°C; 
air velocity: 0.05 m/s; humidity: 45%). In the PASSIVETOB condition, participants were 
exposed to air polluted with tobacco cigarette smoke at a stable CO concentration to 
simulate bar/restaurant levels (23±1ppm; CO90 CO-CO2 analyzer, Martindale Electric 
Ltd., Watford, UK), for one hour inside the same chamber, as previously described (A. 
Flouris, G. Metsios, A. Jamurtas, & Y. Koutedakis, 2010; Flouris, et al., 2009; Flouris, 
et al., 2008; Metsios, et al., 2007). The desired CO concentration of the gas mixture was 
achieved by combustion of cigarettes from various popular brands (i.e., equal number 
of Camel, Davidoff Classic, Gauloises Filter, Original Red Lucky Strike, Marlboro 
Reds, Prince Classic and Silk Cut Purple King Size tobacco cigarettes). Mainstream 
smoke was generated from cigarettes by using an air pump (DYN, Volos, Greece) set at 
an air flow rate of 4 l/min. Cigarettes were half smoked using the air pump and then 
were left lit for 2 min to generate sidestream smoke, and then the rest of the cigarettes 
were smoked. An average of 29.2±0.9 cigarettes was smoked in order to achieve the 
required level of CO in the exposure chamber. In the PASSIVEE-CIG condition, 
participants were exposed to air polluted with e-cigarette vapor for one hour in the 
same chamber. In this case, a simulated a bar/restaurant e-cigarette smoking 
environment was achieved by smoking e-cigarettes via the same air pump set at an air 
flow rate of 4 l/min for the same time as in the PASSIVETOB condition. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 08:53:12 EET - 137.108.70.7
37 
 
In previous experiments (A. Flouris, et al., 2010; Flouris, et al., 2009; Flouris, et 
al., 2008; Metsios, et al., 2007) our research group simulated a passive smoking 
environment by placing lit cigarettes in ashtrays and using nearby fans to circulate the 
air in the room (i.e., 100% sidestream smoke). In the current study, the increased 
oxygen and burn temperature produced by applying air current within the cigarettes via 
the air pump may have resulted in more efficient combustion and "cleaner" smoke.  
Therefore, we conducted a pilot study to assess lung function prior to and following the 
current protocol and the one adopted in our previous studies. Seven never-smokers 
participated in the two conditions that were conducted at the same time on two separate 
days using identical pre-calibrated equipment. Within each individual data collection 
time point (i.e., baseline, immediately post and 1-hour post exposure), Mann–Whitney 
U tests were used to detect changes between the previously used (PASSIVETOB1) and 
the current (PASSIVETOB2) protocol. The results, presented in Table 2, demonstrated 
that lung function tended to be slightly less affected by the current protocol (e.g., FEV1 
and PEF were slightly lower while CO was slightly higher immediately following 
passive smoking in the PASSIVETOB1), yet no statistically significant difference was 
observed between the two protocols (P>0.05). 
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Table 2. Lung function results (mean±sd) across time during the two tobacco cigarette 
passive smoking protocols. 
Protocol Time FeNO CO FVC FEV1 FEV1/FVC PEF FEF25-75 
 Baselin
e 
14.4±7.6 1.0±0.0 5.3±1.1 4.4±0.8 0.8±0.1 9.3±2.2 4.4±1.0 
PASSIVET
OB1 
Post 13.1±7.8 2.9±0.7 5.2±1.0 4.2±0.7 0.8±0.1 8.9±1.8 4.3±1.0 
 1h Post 11.6±8.3 3.7±0.8 5.2±1.1 4.3±0.8 0.8±0.1 9.0±2.0 4.4±1.1 
 Baselin
e 
15.3±8.9 1.0±0.0 5.3±1.1 4.4±0.8 0.8±0.1 9.3±1.9 4.4±1.0 
PASSIVET
OB2 
Post 11.4±8.2 2.7±1.4 5.2±1.0 4.3±0.9 0.8±0.1 9.1±2.0 4.3±1.2 
 1h Post 10.7±9.0 4.0±1.3 5.2±1.1 4.3±0.8 0.8±0.1 9.2±2.2 4.3±1.2 
Note: FeNO = exhaled nitric oxide; CO = exhaled carbon dioxide; FVC = forced vital capacity; FEV1 = forced 
expiratory volume in 1 second; PEF = peak expiratory flow; FEF25-75 = forced expiratory flow in the middle 50% of 
FVC; PASSIVETOB1 = previously-used tobacco cigarette passive smoking protocol; PASSIVETOB2 = current tobacco 
cigarette passive smoking protocol. 
 
 
 
Lung Function  
Spirometry was performed by the same technician according to the American 
Thoracic Society recommendations (American Thoracic Society, 1995) using a portable 
spirometer (Spirobank II; MIR, Rome, Italy) to ensure reliability. Values measured 
included forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), 
FEV1/FVC ratio, peak expiratory flow (PEF), and forced expiratory flow in the middle 
50% of FVC (FEF25-75). Moreover, exhaled CO was assessed using a portable breath 
CO monitor (Breath CO Monitor; Clement Clarke International, Essex, UK) and 
exhaled nitric oxide (FeNO) was measured using a portable NO analyzer (NObreath, 
Bedfont, Rochester, UK) at 50 ml/s exhalation flow.  
 
Cotinine Biochemical Analysis 
Serum cotinine was measured via liquid chromatography mass spectrometry 
(LCMS) analysis using techniques similar to those described earlier by our group (A. 
Flouris, et al., 2010; Flouris, et al., 2009; Flouris, et al., 2008; Metsios, et al., 2007). 
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Veins of the antecubital fossa were accessed for the collection of 5ml of whole 
blood. Blood was centrifuged and serum samples were frozen without delay to -20°C 
until analyzed. Two milliliters (2 ml) of each sample was placed in test tubes. Ketamine 
(10 μl from a 10 ppm solution) was inserted into each sample as an internal standard. 
Further, 1.5 ml ammonium formate (5mM, pH=3.1) was added to each sample that was 
followed by a solid phase extraction step. Column (Varian, bond Elut–C18, 100mg, 1 
ml) activation was executed by adding 1 ml methanol and 1 ml ammonium formate. 
Thereafter, the sample solution was passed through the column and washed with 1 ml 
of water. Elution was performed by 1 ml of methanol containing 5% ammonium 
hydroxide (v/v). The collected solution was acidified by 100 μl HCl (1% in methanol) 
and evaporated under gentle nitrogen steam at 25°C (Miller, Norris, Rollins, Tiffany, & 
Wilkins, 2010). A reconstitution in 100 μl of methanol was followed and the solution 
was promoted to LCMS analysis. 
A LCMS system (Shimadzu LCMS-2010 EV, Shimadzu Co., Kyoto, Japan) 
equipped with an electrospray ionization interface, an autosampler, solvent degasser, 
binary pump, and a heated/cooled column compartment was used for cotinine 
extraction from serum samples. The column was a Discovery C18 Column (25cm x 
4.6mm, 5μm; SupelCo, Bellefonte, USA). Both mass spectrometer and HPLC inlet 
were controlled by Shimadzu LCMS solution software (LCMS Solution version 3) that 
was also used for data acquisition and processing. The instrument was tuned and 
calibrated using autotune procedures recommended by the manufacturer. CDL and heat 
block temperatures were 250°C and 200°C, respectively. The detector voltage was 1.5 
kV and the nebulizing gas flow 1.5 L/min. 
 Twenty μl (20 μl) from each extracted sample were placed in to the 
chromatograph column at a temperature of 45°C. A gradient of 10mM ammonium 
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acetate, pH = 5.2, (solvent A) and an acetonitrile (solvent B) were selected for routine 
use: starting at 10% of solvent B, 90% B (15 min linear ramp), 10% B (5 min). The 
total mobile phase flow rate was 0.6 mL/min. The detection was done in SIM (selected 
ion monitoring) positive mode using ion fragments with m/z 163, 204 for nicotine, m/z 
177, 218 for cotinine and m/z 238, 279 for ketamine. The fragments that were used for 
quantification were m/z 163, m/z 177 and 238 for nicotine, cotinine and ketamine, 
respectively. 
 
Sample Size Estimation 
Given the two distinct subpopulations (i.e., smokers and never-smokers) 
investigated in this study, sample size was determined separately and the highest 
number of subjects required was used. For active smoking in smokers, the minimum 
required sample size was determined using a recent e-cigarette study (Eissenberg, 
2010) where plasma nicotine was measured prior to and immediately following tobacco 
cigarette (2.0 vs. 16.8 ng·ml-1) and e-cigarette (2.0 vs. 2.5 ng·ml-1) active smoking. 
Given the lack of previous passive e-cigarette smoking studies, the minimum required 
sample size for passive smoking in never-smokers was determined using a tobacco 
cigarette passive smoking study (Metsios, et al., 2007) where serum cotinine was 
measured prior to and immediately following a similar 1-hour tobacco cigarette passive 
smoking exposure (8 vs. 23.17 ng·ml-1) and a control exposure (8.27 vs. 9.17 ng·ml-1). 
 Sample size calculations were conducted using G*Power 3.0 (Faul, Erdfelder, 
Lang, & Buchner, 2007). The “Repeated measures: Within factors, ANOVA-approach” 
incorporated in the “F tests” family with “a priori” as the type of power analysis was 
used to calculate the power of the within effect. The “Number of groups” and “Number 
of measurements” fields are set to 1 and 9, respectively. Error probability and “Corr 
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among rep measures” were set to 0.05 and 0.5, respectively, and – since sphericity 
obviously holds in this study – nonsphericity correction was set to 1. The minimum 
required sample size was determined by calculating the variance of the within effect. 
Using the aforementioned published data (Eissenberg, 2010; Metsios, et al., 2007), the 
“Variance explained by special effect” was equal to 14.6 and 16.1 for the active and 
passive smoking, respectively, while the “Variance within groups” was set to 92 = 81 in 
both cases. The resulting minimum required sample size, given a predetermined Type I 
error rate of 0.05, was 8 participants for both occasions. The protocols of power 
analyses and the corresponding central and noncentral distributions are provided in 
figure 4. In order to confidently detect a reasonable departure from the null hypothesis, 
the total sample size studied in each sub-population was nearly doubled to 15 subjects. 
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Figure 5. Protocols of power analyses and the corresponding central and noncentral 
distributions 
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Statistical Analysis 
A priori power calculations demonstrated that a sample size of 15 participants 
per group (i.e., smokers and never-smokers) provided >95% power. In order to focus 
the analyses entirely on the effect of active and passive smoking while removing any 
diurnal variation, values from the two control conditions (i.e., ACTIVECON and 
PASSIVECON) were subtracted from the values of the tobacco cigarette conditions (i.e., 
ACTIVETOB and PASSIVETOB) and the electronic cigarette conditions (i.e., ACTIVEE-
CIG and PASSIVEE-CIG). Friedman tests followed by post hoc Wilcoxon signed-rank 
tests were used to assess changes over time (i.e., prior to, immediately after, and one 
hour after active or passive smoking) during ACTIVETOB, ACTIVEE-CIG, PASSIVETOB, 
and PASSIVEE-CIG on all examined variables (i.e., FVC, FEV1, FEV1/FVC ratio, PEF, 
FEF25-75, CO, FeNO, and cotinine). Within each individual data collection time point, 
Mann–Whitney U tests were used to detect changes between ACTIVETOB and 
ACTIVEE-CIG, as well as between PASSIVETOB and PASSIVEE-CIG. The accepted level 
of significance was P≤0.05. Where applicable, the level of significance was adjusted for 
multiple comparisons using the Bonferroni correction (i.e., 0.05 / n; where n is the 
number of comparisons). As such, levels of significance for the Friedman tests and the 
Wilcoxon signed-rank tests were set at P≤0.002, P≤0.017, respectively. 
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Results 
Results for both active and passive smoking are illustrated in figures 6 and 7 
respectively, while the absolute values appear in tables 3 and 4. Lung function was 
compromised immediately after active and passive tobacco cigarette smoking, while 
after one hour the majority of lung function parameters had returned to normal levels. 
No such changes were observed immediately or 1-hour after active or passive e-
cigarette smoking. Specifically, Friedman tests revealed that FEV1/FVC (χ
2
 = 12.67; P 
= 0.002), CO (χ2 = 26.27; P < 0.001), and cotinine (χ2 = 14.93; P = 0.001) changed 
significantly across time during ACTIVETOB. Post hoc Wilcoxon signed-rank tests 
demonstrated that FEV1/FVC (z = -2.48, P = 0.013) was significantly reduced, while 
CO (z = -3.42, P = 0.001) and cotinine (z = -3.24, P = 0.001) were significantly 
increased immediately following smoking during the ACTIVETOB. One hour following 
smoking in the ACTIVETOB, CO (z = -3.41, P = 0.001) and cotinine (z = -2.90, P = 
0.004) remained significantly higher than normal. In the ACTIVEE-CIG condition, 
results from Friedman tests showed that the only variable that significantly fluctuated 
across time was serum cotinine (χ2 = 18.53; P < 0.001). Post hoc tests revealed an 
increase in cotinine both immediately after (z = -3.29, P = 0.001) and one hour after (z 
= -3.32, P = 0.001) smoking in the ACTIVEE-CIG condition (figure 6). 
Friedman tests revealed that CO (χ2 = 17.18; P < 0.001) changed significantly 
across time during PASSIVETOB. Serum cotinine also showed considerable change 
across time which, however, did not reach our conservative significance level (χ2 = 
10.13; P = 0.006). Post hoc Wilcoxon signed-rank tests demonstrated that the 
FEV1/FVC (z = -2.38, P = 0.017) was reduced whereas CO (z = -3.31, P = 0.001) and 
cotinine (z = -2.96, P = 0.003) were increased immediately following smoking in the 
PASSIVETOB condition. The increased levels of CO (z = -2.99, P = 0.003) and cotinine 
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(z = -2.62, P = 0.009) were observed even one hour after passive smoking in 
PASSIVETOB. Friedman tests for PASSIVEE-CIG showed no fluctuations across time. 
Post hoc tests demonstrated no statistically significant changes immediately following 
smoking in the PASSIVEE-CIG condition. In the same condition, cotinine demonstrated 
an upward trend immediately following smoking, similar to that observed during 
PASSIVETOB, and was significantly increased one hour after the exposure (z = -2.70, P 
= 0.007) (figure 7). 
Given the reduction of FEV1/FVC, it is important to note that FEV1 also 
declined during both ACTIVETOB and PASSIVETOB. However, this effect did not reach 
statistical significance probably due to relatively increased variability. 
 When comparing tobacco cigarette and e-cigarette smoking, Mann–Whitney U 
comparisons showed that the only variable found to be significantly different was CO 
which was increased both immediately following (active smoking: z = -4.39, P < 0.001; 
passive smoking: z = -4.37, P < 0.001) as well as one hour after (active smoking: z = -
3.21, P = 0.001; passive smoking: z = -3.56, P = 0.001) tobacco cigarette smoking 
(figures 6 and 7).  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 08:53:12 EET - 137.108.70.7
46 
 
 
Figure 6. Change from the control condition in all the examined parameters prior to, 
immediately following, as well as 1 hour following active smoking. Results are 
presented as median±mean absolute deviation. Solid lines represent tobacco cigarette 
smoking, while dotted lines represent e-cigarette smoking. Asterisks indicate 
statistically significant change from baseline values, while crosses indicate statistically 
significant difference between e-cigarettes and tobacco cigarettes. 
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Figure 7. Change from the control condition in all the examined parameters prior to, 
immediately following, as well as 1 hour following passive smoking. Graph properties 
are identical to those of figure 6.  
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Table 3. Absolute values (median±mean absolute deviation) for all parameters prior 
to, immediately following, as well as 1 hour following active smoking in smokers.  
 Time FeNO 
(ppb) 
CO 
(ppm) 
FVC 
(L) 
FEV1 
(L) 
FEV1/FV
C 
PEF 
(L/min) 
FEF25-75 
(L) 
Cotinine 
(ng/ml) 
 Baseline 4.5±4.8 7.0±2.5 4.5±0.9 3.5±0.7 0.85±0.05 6.8±2.1 4.2±0.8 41.0±31.0 
CON Post 3.0±4.1 7.0±3.1 4.3±1.1 3.6±0.8 0.84±0.10 7.2±2.2 4.2±1.2 41.3±28.7 
 1h Post 4.5±4.9 5.0±3.0 4.3±1.6 3.6±1.3 0.85±0.21 6.6±2.6 4.1±1.7 40.6±27.6 
 Baseline 5.0±5.5 7.0±2.7 4.5±1.0 3.7±0.7 0.83±0.05 7.3±2.4 3.9±0.8 43.7±31.5 
TOB Post 4.0±4.9 16.0±4.5 4.1±1.1 3.3±0.6 0.78±0.06 6.6±1.9 3.4±0.8 61.3±36.6 
 1h Post 3.0±4.6 14.0±4.6 4.6±1.1 3.5±0.7 0.81±0.06 6.4±2.3 4.1±0.8 60.6±34.3 
 Baseline 4.0±4.5 9.0±2.0 4.4±1.1 3.6±0.8 0.82±0.05 7.1±2.1 3.7±0.9 27.5±25.8 
E-
CIG 
Post 4.0±3.1 7.0±1.7 4.4±1.0 3.6±0.7 0.81±0.06 7.2±2.0 4.0±0.8 42.3±33.5 
 1h Post 4.0±4.2 6.0±1.9 4.4±1.0 3.5±0.7 0.82±0.05 6.5±2.3 3.9±0.7 52.4±36.1 
Note: FeNO = exhaled nitric oxide; CO = exhaled carbon dioxide; FVC = forced vital capacity; FEV1 = forced 
expiratory volume in 1 second; PEF = peak expiratory flow; FEF25-75 = forced expiratory flow in the middle 50% 
of FVC; CON = control condition; TOB = tobacco cigarette active smoking condition; E-CIG = e-cigarette active 
smoking condition. 
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Table 4. Absolute values (median±mean absolute deviation) for all parameters prior 
to, immediately following, as well as 1 hour following passive smoking in never-
smokers.  
 Time FeNO 
(ppb) 
CO 
(ppm) 
FVC 
(L) 
FEV1 
(L) 
FEV1/FVC PEF 
(L/min) 
FEF25-75 
(L) 
Cotinine 
(ng/ml) 
 Baseline 14.0±7.4 1.0±0.1 4.8±1.0 4.1±0.8 0.88±0.06 9.7±1.8 4.6±1.1 1.5±0.7 
CON Post 14.0±6.7 1.0±0.1 4.6±1.0 4.1±0.8 0.89±0.06 9.4±1.5 4.5±1.2 1.7±0.7 
 1h Post 14.0±7.3 1.0±0.2 5.0±1.0 4.1±0.8 0.88±0.06 9.5±1.8 4.8±1.0 1.9±0.6 
 Baseline 15.0±6.3 1.0±0.2 4.8±1.0 4.2±0.8 0.89±0.06 9.2±1.8 4.6±1.2 1.9±0.5 
TOB Post 10.0±7.7 4.0±1.4 4.6±1.0 4.0±0.9 0.86±0.05 9.1±1.8 4.1±1.3 2.6±0.6 
 1h Post 10.0±7.7 4.0±1.5 5.5±1.0 4.0±0.9 0.86±0.05 9.1±2.0 4.2±1.3 2.4±0.9 
 Baseline 10.0±7.1 1.0±0.1 5.1±1.0 4.1±0.8 0.89±0.05 8.9±1.7 4.6±1.2 1.8±0.9 
E-
CIG 
Post 11.0±8.1 1.0±0.1 4.4±1.0 3.9±0.8 0.86±0.05 9.2±2.0 4.8±1.2 2.3±1.2 
 1h Post 10.0±8.1 1.0±0.3 4.5±1.0 4.0±0.8 0.88±0.05 8.5±2.0 4.7±1.1 2.2±0.7 
Note: FeNO = exhaled nitric oxide; CO = exhaled carbon dioxide; FVC = forced vital capacity; FEV1 = forced 
expiratory volume in 1 second; PEF = peak expiratory flow; FEF25-75 = forced expiratory flow in the middle 50% 
of FVC; CON = control condition; TOB = tobacco cigarette active smoking condition; E-CIG = e-cigarette active 
smoking condition. 
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Discussion  
 
In this study we present the first comprehensive assessment regarding the 
impact of acute and short term active and passive e-cigarette smoking on the function 
and inflammation of the lungs, as compared to active and passive tobacco cigarette 
smoking. The results suggest that acute active and passive e-cigarette smoking generate 
a mild lung airflow obstruction and a small increase in lung inflammation that last <1 
hour and appear to be of minimum clinical significance. On the other hand, acute active 
and passive tobacco cigarette smoking increase lung inflammation and undermine lung 
function, as serially shown in previous studies (Eisner, et al., 2007; A. Flouris, et al., 
2010; Flouris, et al., 2009; Flouris, et al., 2008; Metsios, et al., 2007; Yates, et al., 
2001). 
 Chronic lung disease is normally a long-term process. However, even brief 
exposures to air pollution stimulate mechanisms that contribute to its development 
(Flouris, 2009; Flouris, et al., 2009). Acute smoking causes localised lung 
inflammation, platelet aggregation, reduction of the number of eosinophils, suppression 
of repair mechanisms and impairment of the epithelial barrier (van der Vaart, et al., 
2004). All these mechanisms are heavily linked with the development and/or 
exacerbation of chronic lung disease. While it is essential to study the effects of long-
term e-cigarette use, investigating the acute phase of e-cigarette vapor inhalation is 
crucial and represents an essential step in the research agenda (Etter, et al., 2011). 
It is true that technology is not always a benign force and some of the reasons in 
support of skepticism concerning progress are valid (Flouris & Oikonomou, 2010). In 
the case of smoking, however, the progress from tobacco cigarettes to e-cigarettes 
could, potentially, have beneficial effects for public health. That is if the design, 
implementation, and commercialization of this technology adhere to appropriate 
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regulations in order to protect consumer’s health. Till now, neither of these 
requirements has been achieved in a way that ENDS use could be safe and risk-free.  
In our study, the effects of e-cigarettes on lung function and inflammation were 
not vastly different from those generated by tobacco cigarettes. Nevertheless, e-
cigarettes produced a much smaller detrimental impact on the respiratory system; at 
least in the acute phase that was assessed in the present study. Therefore, there is hope 
that with further advancement of this technology in the future, the effects on health may 
be reduced even more. 
It is important to note that the present results apply to the specific e-cigarette 
device and liquid tested and may not describe appropriately the acute usage of other 
devices and/or liquids. Volunteers were ENDS-naive users and it is possible that the 
health effects are different in experienced users. Moreover, puffing topography may 
play a role; in our study the observed changes in lung function and inflammation were 
not produced by extreme and/or prolonged tobacco cigarette or e-cigarette inhalation. 
The protocols used for active and passive smoking have been standardized by our group 
(A. Flouris, et al., 2010; Flouris, et al., 2009; Flouris, et al., 2008; Metsios, et al., 2007) 
and/or others (Bullen, et al., 2010; Vansickel, et al., 2010). Furthermore, the observed 
cotinine levels suggest a moderate and brief inhalation. Yet, our lung function results 
are limited by the impossibility of blinding our participants to active and passive 
smoking. However, suggestibility does not appear to underlie acute physiological 
responses to smoke inhalation (Urch, et al., 1988).  
E-cigarette use is acceptable in indoor spaces in many countries due to lack of 
regulations and/or manufacturers’ assertions that the vapor released does not contain 
any chemicals. It is the first time that passive e-cigarette smoking is tested and even 
though it did not influence lung function or markers of inflammation like FeNO, 
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plasma cotinine was raised significantly on participants 1 hour after exposure to e-
cigarette vapor, implying that nicotine may be present.  
As far as active e-cigarette smoking is concerned, finding show little impact on 
lung function compared to tobacco smoking; however, spirometry may fail to detect the 
initial and possibly mild effects from the short-term inhalation of e-cigarette vapor on 
the respiratory system while repetitive use may provoke significant changes. In another 
study where lung function was normal, e-cigarette use was related to an increase on 
flow resistance detected by impulse osscilometry (IOS); thus it is likely that these 
oncoming pathophysiological changes may not be represented in spirometric findings 
yet (Vardavas, et al., 2011).  
With these in mind, it is concluded that acute active and passive e-cigarette 
smoking generate a mild lung obstruction and a small increase in lung inflammation 
that last <1 hour and appear to be of minimum clinical significance. In contrast, acute 
active and passive tobacco cigarette smoking produce marked lung inflammation and 
undermine lung function. Future research should target the health effects of long-term 
e-cigarette usage, while extensive research via independent organizations must be 
incorporated within the design and implementation of this technology in order to 
protect consumer health.   
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Appendix B: Written consent form 
 
 
 
  
Έντυπο συναίνεσης δοκιμαζόμενου σε ερευνητική εργασία 
 
1. Σκοπός της ερευνητικής εργασίας  
Σκοπός αυτής της εργασίας είναι να μελετηθούν οι βραχυπρόθεσμες επιπτώσεις του 
καπνίσματος, ενεργητικού και παθητικού, συμβατικού και ηλεκτρονικού τσιγάρου, στον 
ανθρώπινο οργανισμό. Ειδικότερα, θα μελετηθούν τυχόν αλλαγές στην λειτουργία των 
πνευμόνων, στο καρδιαγγειακό, το ανοσολογικό και το ενδοκρινικό σύστημα. Το ηλεκτρονικό 
τσιγάρο είναι μια συσκευή προσομοίωσης του συμβατικού, που πρόσφατα έχει προωθηθεί στην 
αγορά ως εναλλακτική μορφή ή ως μέσο διακοπής του καπνίσματος. Είναι κατασκευασμένο 
ώστε να μιμείται τη διαδικασία του καπνίσματος, προσφέροντας όμως στο χρήστη τους έναν 
εναλλακτικό, πιο «υγιεινό» τρόπο καπνίσματος. Σύμφωνα με τους κατασκευαστές τους το 
ηλεκτρονικό τσιγάρο απαλλάσσει τον χρήστη του από τον καπνό, την πίσσα και χιλιάδες άλλες 
τοξικές ουσίες που περιέχουν τα συμβατικά τσιγάρα αλλά και τους ανθρώπους στον 
περιβάλλοντα χώρο από το παθητικό κάπνισμα. 
 
2. Διαδικασία μετρήσεων 
Θα χρειαστεί να έρθεις στο εργαστήριο τρεις φορές, με μεσοδιάστημα 7 ημερών. Θα πρέπει να 
προσέλθεις εγκαίρως, ώστε το πείραμα να ξεκινήσει στις 09:00 ακριβώς (τουλάχιστον 15 λεπτά 
πριν). Θα πρέπει να αποφύγεις την έντονη σωματική δραστηριότητα για 3 ημέρες πριν και να 
είσαι νηστικός (το τελευταίο γεύμα να έχει ολοκληρωθεί στις 11:00μμ το προηγούμενο βράδυ). 
Θα πρέπει να μην έχεις καπνίσει ούτε να έχεις εκτεθεί σε παθητικό κάπνισμα για 12 ώρες πριν 
την έναρξη της έρευνας, δηλαδή από τις 9:00μμ το προηγούμενο βράδυ. Κατά την διάρκεια του 
πειράματος απαγορεύεται η πρόσληψη τροφής, επιτρέπεται η πρόσληψη νερού. 
Καπνιστές: Το πείραμα θα έχει διάρκεια 1,5 ώρας. Πριν το πείραμα θα πρέπει να δώσεις κάποια 
στοιχεία για την καπνιστική σου συνήθεια (από τι ηλικία ξεκίνησες να καπνίζεις, πόσα τσιγάρα 
καπνίζεις την ημέρα και για πόσα χρόνια). Την πρώτη ημέρα θα καπνίσεις 2 τσιγάρα της 
επιλογής σου, μέσα σε διάστημα μισής ώρας. Τη δεύτερη φορά θα καπνίσεις ηλεκτρονικό 
τσιγάρο. Την τρίτη φορά θα «καπνίσεις» ένα μη αναμμένο τσιγάρο της επιλογής σου. Θα 
πραγματοποιηθούν μετρήσεις αμέσως πριν το πείραμα, αμέσως μετά τη λήξη του πειράματος  
και 1 ώρα μετά τη δεύτερη μέτρηση. 
Μη καπνιστές: Το πείραμα θα έχει διάρκεια 2 ωρών. Την πρώτη φορά θα υποβληθείς για 1 ώρα 
σε μέτριο παθητικό κάπνισμα συμβατικού τσιγάρου μέσα σε έναν ειδικά διαμορφωμένο χώρο 
που θα εξομοιώνει τις συνήθεις συνθήκες που επικρατούν σε ένα εστιατόριο/μπαρ. Τη δεύτερη 
φορά θα υποβληθείς σε παθητικό κάπνισμα ηλεκτρονικού τσιγάρου για 1 ώρα. Την τρίτη φορά 
θα περάσεις 1 ώρα σε ένα δωμάτιο με καθαρό αέρα. Θα πραγματοποιηθούν μετρήσεις αμέσως 
πριν το πείραμα, αμέσως μετά τη λήξη του πειράματος, και 1 ώρα μετά τη δεύτερη μέτρηση. 
Οι μετρήσεις θα είναι:  
o Κλινικές.  
Θα κληθείς να φυσήξεις όσο πιο δυνατά μπορείς στο σπιρόμετρο για 3 συνεχόμενες φορές 
ώστε να γίνουν μετρήσεις της πνευμονικής σου λειτουργίας. Επίσης, θα φυσήξεις από μία φορά 
σε φορητούς μετρητές εκπνεόμενου μονοξειδίου του άνθρακα και μονοξειδίου του αζώτου. 
o Εργαστηριακές. Για το σκοπό αυτό, θα πραγματοποιείται αιμοληψία κατά την οποία θα 
λαμβάνονται 15ml αίματος κάθε φορά.  
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3. Κίνδυνοι και ενοχλήσεις 
Κατά την διάρκεια του πειράματος αν είσαι μη καπνιστής υπάρχει κίνδυνος να έχεις κάποια 
δυσφορία από τον καπνό, η οποία δεν θα είναι μεγαλύτερη από αυτήν όταν παρευρίσκεσαι σε 
ένα συνηθισμένο εστιατόριο/μπαρ που καπνίζουν. Οποιαδήποτε στιγμή αισθανθείς κάποιο 
σύμπτωμα που σε προβληματίζει σε παρακαλούμε να το αναφέρεις και θα ληφθεί μέριμνα για 
την προστασία της υγείας και της προσωπικότητάς σου. Ακόμα υπάρχει ένας πολύ μικρός 
κίνδυνος δημιουργίας μώλωπα στην περιοχή του αγκώνα όπου και βρίσκεται η φλέβα από την 
οποία θα πραγματοποιηθεί η αιμοληψία. Θα γίνει κάθε προσπάθεια να ελαχιστοποιηθούν αυτοί οι 
κίνδυνοι. Υπάρχει πρόβλεψη πρώτων βοηθειών και εκπαιδευμένο προσωπικό για κάθε 
ενδεχόμενο. 
 
4. Προσδοκώμενες ωφέλειες 
Τα ευρήματα από την εργασία θα σου δώσουν την δυνατότητα: 
o Να εκτιμήσεις τις βραχυπρόθεσμες επιπτώσεις του καπνίσματος (ενεργητικού και 
παθητικού) συμβατικού και ηλεκτρονικού τσιγάρου στον οργανισμό σου.  
o Να διαπιστώσεις τις βλαβερές συνέπειες αλλά και τα πιθανά οφέλη για την υγεία σου 
που πιθανόν να προκύψουν από την σύγκριση των αποτελεσμάτων. 
o Να οδηγηθείς ακόμη και σε διακοπή του καπνίσματος. 
 
5. Δημοσίευση δεδομένων – αποτελεσμάτων 
Η συμμετοχή σου στην έρευνα συνεπάγεται ότι συμφωνείς με τη δημοσίευση των δεδομένων 
και των αποτελεσμάτων της, με την προϋπόθεση ότι οι πληροφορίες θα είναι ανώνυμες και δε 
θα αποκαλυφθούν τα ονόματα των συμμετεχόντων. Τα δεδομένα που θα συγκεντρωθούν θα 
κωδικοποιηθούν με αριθμό, ώστε το όνομα σου δε θα φαίνεται πουθενά. 
6. Πληροφορίες 
Μη διστάσεις να κάνεις ερωτήσεις γύρω από το σκοπό, τον τρόπο πραγματοποίησης της 
εργασίας ή τον υπολογισμό της λειτουργικής σου ικανότητας. Αν έχεις κάποιες αμφιβολίες ή 
ερωτήσεις, ζήτησέ μας να σου δώσουμε πρόσθετες εξηγήσεις. 
7.Ελευθερία συναίνεσης  
Η άδειά σου να συμμετάσχεις στην εργασία είναι εθελοντική. Είσαι ελεύθερος να μην 
συναινέσεις ή να διακόψεις τη συμμετοχή σου όποτε επιθυμείς. 
 
Διάβασα το έντυπο αυτό και κατανοώ τις διαδικασίες που θα εκτελέσω. Συναινώ να 
συμμετέχω στην εργασία. 
   
Ημερομηνία: __/__/__ 
 
Ονοματεπώνυμο   και 
υπογραφή συμμετέχοντος 
 
 Υπογραφή ερευνητή 
 Ονοματεπώνυμο και 
υπογραφή παρατηρητή 
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Appendix C: Υπεύθυνη δήλωση πνευματικών δικαιωμάτων 
Υπεύθυνη Δήλωση 
Η κάτωθι υπογεγραμμένη Χόρτη Μαρία – ΑΕΜ 10/09, μεταπτυχιακή φοιτήτρια του 
Προγράμματος Μεταπτυχιακών Σπουδών «Άσκηση και Υγεία» του Τμήματος Επιστήμης 
Φυσικής Αγωγής και Αθλητισμού  του Πανεπιστημίου Θεσσαλίας  
 δηλώνω υπεύθυνα ότι αποδέχομαι τους παρακάτω όρους που αφορούν  
(α) στα πνευματικά δικαιώματα της Μεταπτυχιακής Διπλωματικής Εργασίας (ΜΔΕ) μου με 
τίτλο «Βραχυπρόθεσμες επιπτώσεις ενεργητικού και παθητικού καπνίσματος συμβατικού 
και ηλεκτρονικού τσιγάρου στην πνευμονική λειτουργικότητα» (Acute Effects of 
Conventional and Electronic Cigarette Smoking and Second-hand Smoke on Lung Function)  
 (β) στη διαχείριση των ερευνητικών δεδομένων που θα συλλέξω στην πορεία εκπόνησής της:  
1. Τα πνευματικά δικαιώματα του τόμου της μεταπτυχιακής διατριβής που θα προκύψει  
θα ανήκουν σε μένα. Θα ακολουθήσω τις οδηγίες συγγραφής, εκτύπωσης και κατάθεσης 
αντιτύπων της διατριβής στα ανάλογα αποθετήρια (σε έντυπη ή/και σε ηλεκτρονική μορφή).   
2. Η διαχείριση των δεδομένων της διατριβής ανήκει από κοινού σε εμένα και στον 
πρώτο επιβλέποντα καθηγητή. 
3. Οποιαδήποτε επιστημονική δημοσίευση ή ανακοίνωση (αναρτημένη ή προφορική), ή 
αναφορά που προέρχεται από το υλικό/δεδομένα της εργασίας αυτής θα γίνεται με 
συγγραφείς εμένα τον ίδιο, τον κύριο επιβλέποντα ή και άλλους ερευνητές (όπως πχ μέλους 
–ών της τριμελούς συμβουλευτικής επιτροπής), ανάλογα με τη συμβολή τους στην έρευνα ή 
στη συγγραφή των ερευνητικών εργασιών.  
4. Η σειρά των ονομάτων στις επιστημονικές δημοσιεύσεις ή επιστημονικές 
ανακοινώσεις θα αποφασίζεται από κοινού από εμένα και τον κύριο επιβλέποντα της 
εργασίας,  πριν αρχίσει η εκπόνησή της. Η απόφαση αυτή θα πιστοποιηθεί εγγράφως μεταξύ 
εμού και του κ. επιβλέποντα. 
Τέλος, δηλώνω ότι γνωρίζω τους κανόνες περί λογοκλοπής και πνευματικής ιδιοκτησίας 
και ότι θα τους τηρώ απαρέγκλιτα καθ’ όλη τη διάρκεια της φοίτησης και κάλυψης των 
εκπαιδευτικών υποχρεώσεων που προκύπτουν από το ΠΜΣ/τμήμα, αλλά και των 
διαδικασιών δημοσίευσης που θα προκύψουν μετά την ολοκλήρωση των σπουδών μου. 
 
4 Ιουνίου 2012 
Η δηλούσα 
 
Χόρτη Μαρία   
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Appendix D: Meeting diary 
Ονοματεπώνυμο φοιτήτριας: .........Χόρτη Μαρία......................................................... 
Συνάντηση 1η  
 
Ημερομηνία: 15/3/2011      Ώρα:.19:00   Υπογραφή Επιβλέποντος: ........................... 
 
Σκοπός: Θέμα και σχεδιασμός διατριβής  Υπογραφή φοιτητή:...................................... 
 
Επόμενοι Στόχοι: Σύνταξη φόρμας έγγραφης συγκατάθεσης, Πρόταση προς επιτροπή 
βιοηθικής, μελέτη βιβλιογραφίας  
 
Συνάντηση 2η  
 
Ημερομηνία:.29/3/2011     Ώρα:.12:00   Υπογραφή Επιβλέποντος: .............................. 
 
Σκοπός: Πρόταση προς επιτροπή βιοηθικής  Υπογραφή φοιτητή: ........................................ 
 
Επόμενοι Στόχοι: Σχεδιασμός και οργάνωση πειραματικού μέρους 
 
 
Συνάντηση 3η  
 
Ημερομηνία:.3/5/2011     Ώρα:.11:30  Υπογραφή Επιβλέποντος: .............................. 
 
Σκοπός: Οργάνωση πειραματικού μέρους  Υπογραφή φοιτητή:  
 
Επόμενοι Στόχοι: Δημιουργία φορμών αποτελεσμάτων, ανεύρεση εθελοντών, παραγγελία 
ηλεκτρονικών τσιγάρων, προμήθεια και έλεγχος οργάνων (σπιρόμετρο, καπνόμετρο, αναλυτής 
FeNO) 
 
Συνάντηση 4η  
 
Ημερομηνία:   14/9/2011  Ώρα:17:00   Υπογραφή Επιβλέποντος: .............................. 
 
Σκοπός: Οργάνωση πειραματικού μέρους Υπογραφή φοιτητή: …..................................... 
 
Επόμενοι Στόχοι: Προετοιμασία χώρου για μετρήσεις (περιβαλλοντικός θάλαμος), Πιλοτικές 
δοκιμές, Αναλώσιμα οργάνων και εργαστηριακών εξετάσεων  
 
 
Συνάντηση 5η  
 
Ημερομηνία:  29/9/2011   Ώρα: 09:00 Υπογραφή Επιβλέποντος: …..................... 
 
Σκοπός: Πιλοτικές δοκιμές – έναρξη πειράματος Υπογραφή φοιτητή: ..................................... 
 
Επόμενοι Στόχοι: Ανεύρεση εθελοντών, συνεννόηση με εργαστήριο, ημερολόγιο/ 
χρονοδιάγραμμα κλινικών και εργαστηριακών μετρήσεων  
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Συνάντηση 6η  
 
Ημερομηνία:13/10/2011      Ώρα:17:00   Υπογραφή Επιβλέποντος:…......................... 
 
Σκοπός:  Πρόοδος μετρήσεων    Υπογραφή φοιτητή: ...................................... 
 
Επόμενοι Στόχοι: Ολοκλήρωση μετρήσεων, τήρηση χρονοδιαγράμματος  
 
Συνάντηση 7η  
 
Ημερομηνία: 14/11/2011      Ώρα:18:00   Υπογραφή Επιβλέποντος: ............................ 
 
Σκοπός: Στατιστική ανάλυση δεδομένων  Υπογραφή φοιτητή: ...................................... 
 
Επόμενοι Στόχοι: Αποστολή εργαστηριακών δειγμάτων σε Πανεπιστήμιο Κρήτης, έναρξη 
συγγραφής άρθρου προς δημοσίευση  
 
Συνάντηση 8η  
 
Ημερομηνία: 8/12/2011    Ώρα:11:30   Υπογραφή Επιβλέποντος: ........................... 
 
Σκοπός: Άρθρο προς δημοσίευση   Υπογραφή φοιτητή: ...................................... 
 
Επόμενοι Στόχοι: Οριστική μορφή άρθρου προς δημοσίευση, συγγραφή περιλήψεων για 
αποστολή σε πανευρωπαϊκό συνέδριο, έναρξη συγγραφής μεταπτυχιακής διατριβής 
 
Συνάντηση 9η  
 
Ημερομηνία: 8/1/2012      Ώρα:17:00   Υπογραφή Επιβλέποντος: ............................ 
 
Σκοπός: Συγγραφή μεταπτυχιακής διατριβής  Υπογραφή φοιτητή:....................................... 
 
Επόμενοι Στόχοι: Συγγραφή μεταπτυχιακής διατριβής εντός χρονοδιαγράμματος 
 
Συνάντηση 10η  
 
Ημερομηνία:24/5/2012    Ώρα:11:00  Υπογραφή Επιβλέποντος ............................. 
 
Σκοπός: Παρουσίαση μεταπτυχιακής διατριβής  Υπογραφή φοιτητή: ....................................... 
 
Επόμενοι Στόχοι: ολοκλήρωση μεταπτυχιακού προγράμματος 
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